Efficacy of escitalopram for hot flashes in healthy menopausal women: A randomized controlled trial

JAMA

Volumn 305, Issue 3, 2011, Pages 267-274

  Freeman, Ellen W ^a   Guthrie, Katherine A ^b   Caan, Bette ^e   Sternfeld, Barbara ^e   Cohen, Lee S ^f   Joffe, Hadine ^f   Carpenter, Janet S ^g   Anderson, Garnet L ^b   Larson, Joseph C ^b   Ensrud, Kristine E ^h   Reed, Susan D ^c   Newton, Katherine M ^d   Sherman, Sheryl ⁱ   Sammel, Mary D ^a   LaCroix, Andrea Z ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d GROUP HEALTH RESEARCH INSTITUTE   (United States)

^e DIVISION OF RESEARCH   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g INDIANA UNIVERSITY SCHOOL OF NURSING   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; PLACEBO;

ADULT; APPETITE; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; ENTEROPATHY; FATIGUE; FEMALE; FOLLOW UP; HOT FLUSH; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MENOPAUSE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SIDE EFFECT; STOMACH DISEASE; SWEATING; UNSPECIFIED SIDE EFFECT; VIVID DREAM; VOMITING; XEROSTOMIA;

EID: 78751532610     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.2016     Document Type: Article

References (29)

1. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med. 2004;140(3):184-188.
2. Heiss G, Wallace R, Anderson GL, et al; WHI Investigators. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008;299(9):1036-1045.
3. National Institutes of Health. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med. 2005;142(12 pt 1):1003-1013. (Pubitemid 40840315)
4. Nedrow A, Miller J, Walker M, Nygren P, Huffman LH, Nelson HD. Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review. Arch Intern Med. 2006;166(14):1453-1465. (Pubitemid 44125864)
5. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA. 2006;295(17):2057-2071.
6. Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol. 2009;27(17):2831-2837.
7. Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol. 2009;200(2):172.e1-172.e10.
8. Suvanto-Luukkonen E, Koivunen R, Sundström H, et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause. 2005;12(1):18-26. (Pubitemid 40204889)
9. Kalay AE, Demir B, Haberal A, Kalay M, Kandemir O. Efficacy of citalopram on climacteric symptoms. Menopause. 2007;14(2):223-229.
10. Grady D, Cohen B, Tice J, Kristof M, Olyaie A, Sawaya GF. Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial. Obstet Gynecol. 2007;109(4):823-830. (Pubitemid 46559068)
11. Barton DL, LaVasseur BI, Sloan JA, et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol. 2010;28(20):3278-3283.
12. Defronzo Dobkin R, Menza M, Allen LA, et al. Escitalopram reduces hot flashes in nondepressed menopausal women: a pilot study. Ann Clin Psychiatry. 2009;21(2):70-76.
13. Soares CN, Arsenio H, Joffe H, et al. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life. Menopause. 2006;13(5):780-786.
14. Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health. 2006;96(7):1226-1235.
15. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31(1):103-115.
16. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613.
17. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-1097.
18. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci. 1974;19(1):1-15.
19. Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment: double-blind, placebo-controlled trial. Br J Psychiatry. 2000;176:363-368.
20. Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med. 2006;145(12):869-879.
21. Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol. 2005;23(28):6919-6930.
22. Berendsen HH. The role of serotonin in hot flushes. Maturitas. 2000;36(3):155-164.
23. Wyrwich KW, Spratt DI, Gass M, Yu H, Bobula JD. Identifying meaningful differences in vasomotor symptoms among menopausal women. Menopause. 2008;15(4 pt 1):698-705.
24. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA. 2004;291(13):1610-1620.
25. Appling S, Paez K, Allen J. Ethnicity and vasomotor symptoms in postmenopausal women. J Womens Health (Larchmt). 2007;16(8):1130-1138.
26. Whiteman MK, Staropoli CA, Langenberg PW, McCarter RJ, Kjerulff KH, Flaws JA. Smoking, body mass, and hot flashes in midlife women. Obstet Gynecol. 2003;101(2):264-272.
27. Simpkins JW, Brown K, Bae S, Ratka A. Role of ethnicity in the expression of features of hot flashes. Maturitas. 2009;63(4):341-346.
28. Guttuso T, Evans M. Minimum trial duration to reasonably assess long-term efficacy of nonhormonal hot flash therapies. J Womens Health (Larchmt). 2010;19(4):699-702.
29. Loprinzi CL, Diekmann B, Novotny PJ, Stearns V, Sloan JA. Newer antidepressants and gabapentin for hot flashes: a discussion of trial duration. Menopause. 2009;16(5):883-887.